» Articles » PMID: 15824172

Genotyping of Patients with Sporadic and Radiation-associated Meningiomas

Overview
Date 2005 Apr 13
PMID 15824172
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Ionizing radiation is the most established risk factor for meningioma formation. Our aim was to evaluate the main effect of selected candidate genes on the development of meningioma and their possible interaction with ionizing radiation in the causation of this tumor. The total study population included 440 cases and controls: 150 meningioma patients who were irradiated for tinea capitis in childhood, 129 individuals who were similarly irradiated but did not develop meningioma, 69 meningioma patients with no previous history of irradiation, and 92 asymptomatic population controls. DNA from peripheral blood samples was genotyped for single nucleotide polymorphisms (SNP) in 12 genes: NF2, XRCC1, XRCC3, XRCC5, ERCC2, Ki-ras, p16, cyclin D1, PTEN, E-cadherin, TGFB1, and TGFBR2. SNP analysis was done using the MassArray system (Sequenom, San Diego, CA) and computerized analysis by SpectroTYPER. Logistic regressions were applied to evaluate main effect of each gene on meningioma formation and interaction between gene and radiation. Intragenic SNPs in the Ki-ras and ERCC2 genes were associated with meningioma risk (odds ratio, 1.76; 95% confidence interval, 1.07-2.92 and odds ratio, 1.68; 95% confidence interval, 1.00-2.84, respectively). A significant interaction was found between radiation and cyclin D1 and p16 SNPs (P for interaction = 0.005 and 0.057, respectively). Our findings suggest that Ki-ras and ERCC2 SNPs are possible markers for meningioma formation, whereas cyclin D1 and p16 SNPs may be markers of genes that have an inverse effect on the risk to develop meningioma in irradiated and nonirradiated populations.

Citing Articles

Association of county-level socioeconomic status with meningioma incidence and outcomes.

Pugazenthi S, Price M, De La Vega Gomar R, Kruchko C, Waite K, Barnholtz-Sloan J Neuro Oncol. 2023; 26(4):749-763.

PMID: 38087980 PMC: 10995507. DOI: 10.1093/neuonc/noad223.


Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy.

Yarabarla V, Mylarapu A, Han T, McGovern S, Raza S, Beckham T Front Oncol. 2023; 13:1137849.

PMID: 37675219 PMC: 10477988. DOI: 10.3389/fonc.2023.1137849.


Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.

Maggio I, Franceschi E, Di Nunno V, Gatto L, Tosoni A, Angelini D Diagnostics (Basel). 2021; 11(10).

PMID: 34679551 PMC: 8534341. DOI: 10.3390/diagnostics11101852.


Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.

Maggio I, Franceschi E, Tosoni A, Di Nunno V, Gatto L, Lodi R CNS Oncol. 2021; 10(2):CNS72.

PMID: 34015955 PMC: 8162186. DOI: 10.2217/cns-2021-0003.


Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Abbritti R, Polito F, Cucinotta M, Lo Giudice C, Caffo M, Tomasello C Cancer Genomics Proteomics. 2016; 13(5):369-79.

PMID: 27566655 PMC: 5070626.